A Restorative Approach to IOP Control
Both SLT and ABiC™ work to control IOP by a process of restoration of the natural outflow pathways. This is in contrast to traditional glaucoma surgeries and other MIGS procedures, which attempt to mechanically change or bypass the pathway of aqueous outflow. SLT stimulates a process of cellular regeneration to create a healthier, more porous trabeculasr meshwork (TM) structure, while ABiC™ flushes out the natural outflow channels, without damaging tissue and without leaving behind a stent or shunt.
SLT: First-Line, Second Line and Beyond
A simple in-office procedure, selective laser trabeculoplasty (SLT) has been shown to lower IOP as effectively as medication, and to offer a consistent safety profile. Best of all, it is efficacious at every stage of the glaucoma treatment algorithm. A highly effective primary therapy option, especially in non-compliant patients, SLT can also reduce the number of medications required to control IOP. On average, SLT achieves a reduction in IOP of 30% when used as a first-line option.
|“SLT has the potential to become the go-to glaucoma treatment. Perhaps most exciting are the findings from both published studies and surgical experiences which show that SLT is as an effective alternative to medications in patients with newly-diagnosed glaucoma. Therefore, not only can SLT eliminate or at least reduce the need for expensive and inconvenient eye drops, it can help to preserve vision and delay or even prevent complicated, invasive surgical interventions.”
Savak Teymoorian, MD, MBA
ABiC: A Truly Comprehensive MIGS
Ab-interno canaloplasty (ABiC) is a new Minimally-Invasive Glaucoma Surgery (MIGS) procedure that can comprehensively restore the natural outflow pathways in glaucoma patients. In contrast to other MIGS procedures, which treat only one aspect of aqueous outflow, ABiC™ successfully and comprehensively addresses all aspects of potential outflow resistance and is designed to access, catheterize and viscodilate the trabecular meshwork, Schlemm canal and the distal outflow system, beginning with the collector channels. During the ab-interno MIGS procedure, ABiC™ utilizes a process of viscodilation of Schlemm’s canal to flush out the natural outflow channels, without damaging tissue and without leaving behind a stent or shunt – achieving an average reduction in mean IOP of 30%, combined with a 50% reduction in medication burden.*
|“Rather than trying to mechanically change or bypass the pathway of aqueous outflow, ABiC acts to restore the natural outflow process by targeting all aspects of the outflow system. That is, the trabecular meshwork, Schlemm canal, and the collector channels. This is an important distinction of the procedure—especially considering that it is not always understood where the point of maximum resistance lies. It therefore makes sense to apply a procedure that comprehensively addresses the entire outflow system.”
Mark J. Gallardo, MD
*228-eye ABiC 12-Month Case Series Data, presented at ASCRS 2016. Data on file. Ellex Medical.